Provided by Tiger Trade Technology Pte. Ltd.

Eli Lilly

854.96
-19.0400-2.18%
Volume:2.80M
Turnover:2.39B
Market Cap:808.27B
PE:37.25
High:869.02
Open:864.24
Low:850.51
Close:874.00
52wk High:1,133.95
52wk Low:623.78
Shares:945.38M
Float Shares:945.00M
Volume Ratio:1.01
T/O Rate:0.30%
Dividend:6.00
Dividend Rate:0.70%
EPS(TTM):22.95
EPS(LYR):22.95
ROE:101.16%
ROA:19.42%
PB:30.46
PE(LYR):37.25

Loading ...

Earning Preview: Eli Lilly Q1 Revenue Is Expected to Increase by 39.65%, and Institutional Views Are Bullish

Earnings Agent
·
Apr 23

Notable companies reporting before tomorrow’s open

TIPRANKS
·
1 hour ago

Eli Lilly Expected to Post Higher 1Q Profit, Revenue on Continued Weight-Loss Drug Demand -- Earnings Preview

Dow Jones
·
1 hour ago

Eli Lilly Stock (LLY) Falls as Canada Approves Generic Weight-Loss Drugs

TIPRANKS
·
Yesterday

MDB Capital report says retatrutide hits 28.7% weight loss, shifts obesity drug race to IP

Reuters
·
Yesterday

Eli Lilly investors look for insight into Foundayo launch data, Reuters says

TIPRANKS
·
Yesterday

PREVIEW-Eli Lilly investors are eager for Foundayo insight after early launch data

Reuters
·
Yesterday

BRIEF-FuturHealth Offers Eli Lilly’s Oral GLP‑1 Orforglipron, Expanding Non‑Injectable Access

Reuters
·
Yesterday

Futurhealth Among First to Offer Eli Lilly's Oral Glp-1, Orforglipron, Expanding Access to Next-Generation, Non-Injectable Treatment

THOMSON REUTERS
·
Yesterday

Eli Lilly Emerges as Top Contender in Pharma's AI Arms Race with $2.25 Billion Profluent Partnership for DNA Editing Tech

Stock News
·
Apr 28

Analysts Offer Insights on Healthcare Companies: Qiagen (QGEN), Eli Lilly & Co (LLY) and Janux Therapeutics Inc (JANX)

TIPRANKS
·
Apr 28

Profluent, Lilly partner in genetic medicine deal worth up to $2.25 billion

Reuters
·
Apr 28

Profluent Announces Strategic Partnership With Lilly to Develop AI-Designed Recombinases for Genetic Medicine

THOMSON REUTERS
·
Apr 28

Boehringer-Zealand drug leads to 16.6% weight loss in late-stage trial

Reuters
·
Apr 28

Earnings Preview: Eli Lilly's Q1 Report – Strong Growth Expected, Focus on Foundayo Launch and Post-GLP-1 Pipeline

Stock News
·
Apr 28

Boehringer: Weight Loss of 16.6% in Survodutide Group After 76 Weeks Compares With 3.2% in Placebo Group

THOMSON REUTERS
·
Apr 28

Deals of the day-Mergers and acquisitions

Reuters
·
Apr 28

Top Midday Stories: Microsoft, OpenAI Amend Agreement; Qualcomm Reportedly Collaborating With OpenAI on Smartphone AI Chip

MT Newswires Live
·
Apr 27

As Investors Focus on Lilly's Foundayo, They May Be Overlooking Another Key Catalyst -- Barrons.com

Dow Jones
·
Apr 27

BUZZ-Leerink lowers PT of Eli Lilly, maintains 'outperform' rating

Reuters
·
Apr 27